Overview

Pembrolizumab as Neoadjuvant Treatment in HCC

Status:
Unknown status

Trial end date:
2020-10-31

Target enrollment:

Participant gender:

Summary

The aim of this study is to elucidate the utility of the immune checkpoint inhibitor pembrolizumab in preventing the recurrence of HCC when administered before and after curative surgery or ablation.

Phase:

Phase 2

Details

Lead Sponsor:

Kindai University

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab